Based on the fact that you are studying an article about innovative solutions for the treatment of liver cancer and liver metastases — a direction that includes complex surgical, interventional and systemic treatment methods (e.g. TACE, RFA, SIRT, robotic surgery and targeted therapy) — my detailed and voluminous query will focus on comparing the effectiveness of these methods and the selection criteria:

Since the choice of the optimal treatment strategy for malignant liver neoplasms (primary hepatocellular carcinoma or colorectal cancer metastases) depends on a number of factors, including the size, number and localization of tumors, as well as the general condition of the patient and the functional reserve of the liver, how do the leading oncology centers represented on Booking Health objectively compare such highly effective local methods as radioembolization (SIRT) and radiofrequency ablation (RFA/MWA)? What specific clinical indicators and contraindications are used to clearly favor, for example, robotic liver resection over minimally invasive interventional radiology, especially in patients with marginally resectable multiple metastases, and what is the expected 5-year survival rate associated with each of these methods in leading German or Israeli clinics? Additionally, given the need to integrate local treatment with systemic therapy, are there standard protocols that determine when to start or resume targeted therapy or immunotherapy relative to the interventional procedure, and does the total cost of treatment include a multidisciplinary consultation with a surgeon, interventional radiologist, and medical oncologist to develop an individual plan?